Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Osteoporosis 1Neoplasms 1Neoplasm Metastasis 1Hypogonadism 1Genetic Diseases, Inborn 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × Alendronate × Clear all
NCT00019695 2024-03-04

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

NCT00048841 2010-03-02

Prevention of Osteoporosis in Men With Prostate Cancer

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 3 Completed
112 enrolled
Genitourinary

Hypogonadism, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡